|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Supplemental** **Table 2.** Blood products administered peri-procedure (PDT) according to Group A (no major complications) or Group B (major complications) | | | | | | |
| **Variable** | prior to PDT  No of pts | | 24 h post-PDT  No of pts | | 48 h post-PDT  No of pts | |
|  | Group A | Group B | Group A | Group B | Group A | Group B |
| **RBC (units)** \* | | | | | | |
| **0** | 43 | 9 | 39 | 5 | 46 | 4 |
| **1** | 6 | 1 | 11 | 5 | 5 | 1 |
| **2** | 6 | 0 | 5 | 0 | 4 | 5 |
| **FFP (units)** | | | | | | |
| **0** | 55 | 10 | 55 | 9 | 54 | 9 |
| **1** | 0 | 0 | 0 | 0 | 0 | 0 |
| **2** | 0 | 0 | 0 | 1 | 1 | 1 |
| **Platelets (units)** | | | | | | |
| **0** | 41 | 10 | 43 | 9 | 49 | 8 |
| **1** | 8 | 0 | 7 | 1 | 5 | 2 |
| **2** | 6 | 0 | 5 | 0 | 1 | 0 |
| **Cryoprecipitate (units)** \*\* | | | | | | |
| **0** | 43 | 6 | 50 | 7 | 49 | 8 |
| **1** | 2 | 0 | 2 | 0 | 2 | 1 |
| **2** | 10 | 4 | 3 | 3 | 4 | 1 |
| **Fibrinogen (units)** | | | | | | |
| **0** | 54 | 10 | 54 | 10 | 54 | 10 |
| **1** | 0 | 0 | 0 | 0 | 0 | 0 |
| **2** | 1 | 0 | 1 | 0 | 1 | 0 |
| **TXA acid (g)** \*\*\* | | | | | | |
| **0** | 45 | 9 | 46 | 6 | 50 | 6 |
| **1** | 5 | 1 | 5 | 3 | 3 | 3 |
| **2** | 5 | 0 | 4 | 1 | 2 | 1 |

PDT, percutaneous dilatational tracheostomy; RBC, packed red blood cells; FFP, fresh frozen plasma; PLT, bag of pooled platelets; TXA, tranexamic acid

\*P<0.001 between group B and A 48h post-PDT

\*\*P<0.05 between group B and A 24h post-PDT

\*\*\*P<0.05 between group B and A 48h post-PDT